Test Price
2,800 AED✅ Home Collection Available
PLA2G6 Gene: Infantile Neuroaxonal Dystrophy Type 1 (INAD) Genetic Test in UAE | 2,800 AED | DHA Guidelines
Executive Summary & Core Metrics
Accurate genetic screening for PLA2G6 mutations to detect Infantile Neuroaxonal Dystrophy Type 1 (INAD) with 99.9% diagnostic sensitivity, adhering to highest UAE quality and data privacy standards.
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited NGS processing.
- Premium Logistics: Paid hospital‑grade home collection (8 AM–11 PM) with ISO‑certified cold‑chain transport.
- Clinical Guidance: Complimentary telephonic post‑test counselling with a DHA‑licensed medical geneticist.
- Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The PLA2G6 Genetic Test examines the entire coding region of the PLA2G6 gene to identify pathogenic variants responsible for Infantile Neuroaxonal Dystrophy Type 1 (INAD), a rare fatal neurodegenerative disorder. This advanced genetic analysis detects PLA2G6 mutations causing infantile neuroaxonal dystrophy with high diagnostic accuracy.
| Feature | Our NGS Test (DNA Labs UAE) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Methodology | Next Generation Sequencing (full‑gene, all exons) | Sanger sequencing (selected amplicons only) |
| Precision | 99.9% analytical sensitivity | ~99% sensitivity, limited by target coverage |
| Turnaround | 3–4 weeks | 6–8 weeks for equivalent coverage |
| Genetic Counselling | Pre‑ and post‑test tele‑counselling included | Often requires separate referral |
Pre‑Test Requirements
- A clinical history of the patient must be provided.
- Mandatory genetic counselling session to draw a pedigree chart of affected family members.
- Sample: 2‑5 mL whole blood (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
- No special fasting or medication cessation required; continue prescribed treatments.
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I fully appreciate the emotional weight carried by families seeking answers for progressive neurological decline in a child. This genetic test is not merely a laboratory result – it is a compass for early supportive care, accurate prognosis, and informed family planning. Please always interpret any test finding in the context of a thorough neurological examination and, if necessary, brain MRI.”
— Lina Osama Zaki Quteineh, DHA Registration ID: 9294403, Consultant Medical Genetics.
Medication Advisory
Medication Advisory:
Do not discontinue any prescribed medications, anti‑seizure drugs, or nutritional support without consulting your treating neurologist.
Exclusion Criteria & Emergency Red Flags
- Active bleeding disorder or severe thrombocytopenia – inform the phlebotomist before collection.
- Patients on high‑dose anticoagulants may require specialist venous access; contact us in advance.
- If the child experiences sudden loss of consciousness, uncontrolled seizures, or respiratory distress, seek emergency medical attention immediately – do not wait for the test result.
Patient FAQ & Clinical Guidance
1. What does the PLA2G6 genetic test detect and why is it recommended?
The PLA2G6 gene test detects pathogenic mutations causing infantile neuroaxonal dystrophy type 1 (INAD), a severe neurodegenerative disorder presenting in early childhood with regression of motor and cognitive abilities. Neurologists and pediatricians order this test when clinical symptoms such as hypotonia, spasticity, vision loss, and MRI findings suggest INAD. A positive result confirms the diagnosis, guides management, and enables genetic counselling for future pregnancies.
2. How accurate is the genetic test compared to older methods?
Our NGS‑based test provides 99.9% analytical sensitivity for point mutations and small insertions/deletions across all PLA2G6‑coding exons, significantly outperforming Sanger sequencing in speed and coverage. This method is endorsed by current DHA guidelines for rare diseases because it reduces false‑negative rates and identifies both known and novel variants. Results are interpreted using curated clinical databases, and each report is reviewed by a molecular geneticist.
3. Will my insurance cover the cost, and how can I verify?
Many UAE insurers now include rare‑disease genetic testing under inpatient or outpatient benefits, and our team verifies your coverage directly via WhatsApp before sample collection. Send your Emirates ID and insurance card to +971 54 548 8731 for a free benefits check. We are also listed with Daman, Thiqa, NextCare, and other major networks. Self‑pay options are available at 2,800 AED, with flexible installment plans upon request.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, stored securely, and accessed only by authorized clinical personnel. Clinical testing safety and patient consent adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | PLA2G6 Gene: Infantile Neuroaxonal Dystrophy Type 1 (INAD) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood (2-5 mL EDTA), extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) – full gene, all exons |
| ICD-10-CM Code | G31.89 |
| LOINC Code | 78146-2 |
| DHA Facility License & Laboratory Address | DHA License No: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians